Biotech
-
Novo bags €430M Staten buyout option to boost cardiovascular disease pipeline
Novo Nordisk has landed an option to buy Staten Biotechnology in a €430 million ($485 million) deal. The agreement gives…
Read More » -
Doug Disraeli D.D.S. Offers Tips on How to Stick to Your Daily Flossing Resolutions
SAN DIEGO, Dec. 28, 2018 (GLOBE NEWSWIRE) — With the vacation season amongst us, Dr. Doug Disraeli is aware of…
Read More » -
Harpoon files $86M IPO to help fund its T-cell engager platform
Fresh off elevating $70 million by a collection C spherical simply over a month in the past, Harpoon Therapeutics introduced…
Read More » -
Innovent buys Chinese rights to Incyte drugs for $40M upfront
Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in growth at Incyte. The agreement…
Read More » -
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
Australian biotech Imugene says its HER2 vaccine hit the mark in a part 1b trial, establishing a part 2 examine…
Read More » -
Entrada emerges with $59M to fund the delivery of biologic therapies into the cell
Entrada Therapeutics has debuted with a $59 million sequence A and a plan to ship biologic therapies intracellularly to deal…
Read More » -
Idorsia’s selatogrel hits goals in phase 2 cardiovascular trials
Idorsia’s P2Y12 receptor antagonist selatogrel has considerably inhibited platelet aggregation in two phase 2 trials. The major endpoint successes in…
Read More » -
Sophiris slides on prostate cancer data but vows to press on
Sophiris Bio is adamant that it’s going to advance its lead drug topsalysin into section 3 testing, after a second…
Read More » -
Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US Stockholm Stock Exchange:OV
Company NewsOncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US Hørsholm,…
Read More » -
Lexicon pain drug advances after clearing early clinical test
A part 1a trial of Lexicon Pharmaceuticals’ LX9211 has met its main aims. The examine discovered the AAK1 inhibitor was…
Read More »